PVLA logo

PVLA
Palvella Therapeutics Inc

258
Mkt Cap
$1.78B
Volume
202,848.00
52W High
$151.18
52W Low
$20.20
PE Ratio
-33.50
PVLA Fundamentals
Price
$130.20
Prev Close
$124.18
Open
$125.67
50D MA
$114.36
Beta
1.09
Avg. Volume
290,093.23
EPS (Annual)
-$3.71
P/B
54.94
Rev/Employee
$0.00
$1,138.08
Loading...
Loading...
News
all
press releases
Palvella Therapeutics (NASDAQ:PVLA) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Palvella Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are covering the company, MarketBeat.com...
MarketBeat·13d ago
News Placeholder
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Investment analysts at Lifesci Capital lowered their FY2026 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to...
MarketBeat·14d ago
News Placeholder
HC Wainwright Brokers Decrease Earnings Estimates for PVLA
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of Palvella Therapeutics in a research note issued...
MarketBeat·14d ago
News Placeholder
What is HC Wainwright's Estimate for PVLA Q1 Earnings?
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Palvella Therapeutics in a report issued on...
MarketBeat·15d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00
Chardan Capital lifted their price target on Palvella Therapeutics from $210.00 to $240.00 and gave the stock a "buy" rating in a report on Tuesday...
MarketBeat·17d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Trading 14.4% Higher - Should You Buy?
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 14.4% - Here's What Happened...
MarketBeat·17d ago
News Placeholder
Palvella Therapeutics Q4 Earnings Call Highlights
Palvella Therapeutics (NASDAQ:PVLA) executives used the company's full-year 2025 financial results call to highlight clinical progress across its rare disease pipeline, outline upcoming regulatory...
MarketBeat·17d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) announced its earnings results on Tuesday. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.13...
MarketBeat·17d ago
News Placeholder
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
Key PointsAn executive at Palvella Therapeutics reported selling 4,302 common shares for approximately $508,000 on March 18, 2026...
Nasdaq News: Markets·23d ago
<
1
2
...
>

Latest PVLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.